Eltrekibart

Eltrekibart is Eli Lilly's investigational antibody that neutralizes the seven ELR+ CXC chemokines (CXCL1, 2, 3, 5, 6, 7, and 8) that recruit neutrophils through CXCR1 and CXCR2. Three programs are visible: a completed 67-patient Phase 2 monotherapy trial in hidradenitis suppurativa (NCT04493502) with topline results published in JAAD October 2025 [3], a larger 352-patient confirmatory HS Phase 2 (NCT06046729) currently active [2], and a 140-patient Phase 2 combination trial in ulcerative colitis pairing eltrekibart with Lilly's own IL-23 blocker mirikizumab (NCT06598943, recruiting) [1]. The published HS data are equivocal: HiSCR50 at week 16 was 48.9% on eltrekibart (600 mg IV q2w) vs 31.8% on placebo, p=0.19, missing prespecified statistical significance with the 67-patient sample. A prespecified Bayesian augmented-control analysis using historical placebo data lifted the effective comparison to 65.6% vs 32.3% with 99.9% posterior probability of superiority [3]. Lilly clearly read that as a positive signal - they greenlit the 352-patient confirmatory study and the UC combination. The UC combination is the more interesting commercial bet: pairing neutrophil-targeted blockade with the IL-23 axis attacks two distinct inflammatory arms. Worth tracking, but the headline 'first real human efficacy readout' missed its frequentist primary endpoint and the conviction case rests on the augmented-control reanalysis.

Novel compound, never approved anywhere. Three Phase 2 programs known. The completed 67-patient HS Phase 2 (NCT04493502) randomized 2:1 to eltrekibart 600 mg IV every 2 weeks vs placebo for 16 weeks; results published by Forman, Patel, Kimball and colleagues in JAAD, online October 5, 2025 [3]. The larger 352-patient confirmatory HS Phase 2 (NCT06046729) is active, primary endpoint HiSCR50 at week 16 [2]. The UC trial (NCT06598943) pairs eltrekibart with mirikizumab in moderately-to-severely active ulcerative colitis, enrollment target 140, currently recruiting, primary endpoint clinical remission at week 12 by modified Mayo score [1]. No FDA designations have been disclosed for any program - no breakthrough therapy, fast track, orphan, or RMAT status announced. That absence is informative. The missed frequentist primary endpoint in NCT04493502 also explains why Lilly is running a larger confirmatory study before moving to Phase 3. Next inflection points: NCT06046729 HS readout (estimated H2 2026 to H1 2027 based on prior enrollment timelines) and the UC Phase 2 primary endpoint readout (estimated H1 to H2 2027 given NCT06598943 began recruiting in late 2024 with a 12-week primary endpoint and standard 18-24 month enrollment for IBD combination trials).

Think of inflammation as a fire drill. When tissue is damaged or infected, cells release chemical sirens called chemokines that pull immune cells to the site. The ELR+ CXC chemokines are a family of seven proteins (CXCL1, 2, 3, 5, 6, 7, and 8/IL-8) that specifically recruit neutrophils, the first-responder white blood cells. They bind two receptors called CXCR1 and CXCR2 on neutrophils and basically yell 'come here.' In ulcerative colitis, neutrophils flood the colon lining and drive the tissue destruction behind bloody diarrhea. The same biology operates in hidradenitis suppurativa, where neutrophilic abscesses are a defining histologic feature. Existing biologics like IL-23 blockers (mirikizumab, risankizumab) and TNF blockers (infliximab, adalimumab) act upstream, but a meaningful subset of patients keep showing neutrophilic inflammation even after those drugs are on board. Eltrekibart is a humanized monoclonal antibody that blocks all seven ELR+ CXC chemokines simultaneously, choking off the recruitment signal from every direction. That's different from blocking CXCR1/CXCR2 receptors directly with small molecules - an approach that has been tried with reparixin, navarixin, and danirixin across COPD and severe asthma, and has mostly failed. By neutralizing the ligands instead of the receptors, Lilly is betting on cleaner pharmacology and less interference with bone marrow neutrophil production. The mechanism is biologically reasonable but not genetically validated. There's no human loss-of-function evidence showing CXCL8 ablation protects from UC, so the case rests on tissue biology and the hypothesis that IL-23-refractory patients fail because of residual neutrophil recruitment.

Three trials matter. NCT04493502 (completed, published) was a 2:1 randomized double-blind placebo-controlled Phase 2 in 67 adults with moderate-to-severe HS, eltrekibart 600 mg IV every 2 weeks vs placebo, 16-week treatment [3]. Primary endpoint HiSCR50: ≥50% reduction in total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining fistula count from baseline. Results: 48.9% (23/47) eltrekibart vs 31.8% (~7/20) placebo, p=0.19, 95% CI on the difference -7.3 to 41.4 - missed the prespecified frequentist primary. A prespecified Bayesian augmented-control analysis pooling external historical placebo data yielded 65.6% vs 32.3%, posterior probability of superiority 99.9%, 61.9% probability of ≥30 percentage-point difference [3]. NCT06046729 is the 352-patient confirmatory HS Phase 2 designed to provide a definitive frequentist readout and presumably to be the Phase 3 enabling study [2]. The UC trial (NCT06598943) tests eltrekibart plus mirikizumab against mirikizumab alone, 140 patients, primary endpoint clinical remission at week 12 by modified Mayo score [1]. Mirikizumab monotherapy already produces clinical remission rates around 24% in induction studies, so the combination needs to clearly exceed that; a 10-15 percentage-point delta is meaningful, less gets dismissed as noise at this sample size. Dosing for the UC combination has not been publicly disclosed in detail. What's not visible publicly: biomarker stratification. Lilly hasn't disclosed enrichment for high-IL-8 patients or any neutrophilic inflammatory signature.

Our model gives this drug a 17% chance of eventually being approved. That figure starts from a historical baseline of about 30% for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and its sponsor. The estimate rises because the sponsor has a strong track record of getting drugs approved and the trial has more secondary endpoints than usual, and falls because earlier-phase results were weak or limited and the trial uses a randomized design. The remaining factors were close to average for this stage, so they left the estimate near where the base rate placed it.

Efficacy risk first. The published HS trial missed its prespecified frequentist primary endpoint (p=0.19). The conviction case relies on a Bayesian augmented-control analysis, which is methodologically valid but regulatorily contested when used as the primary basis for approval. NCT06046729 will need to deliver a clean frequentist result. For UC, the mechanism assumes residual neutrophil-driven inflammation is the limiting factor in IL-23-refractory disease. Plausible, but unproven in humans. The 140-patient UC trial is statistically tight for detecting an additive effect against an active comparator. Safety risk is the bigger watch. Neutrophils are the immune system's antibacterial frontline. Blocking all seven ELR+ CXC chemokines at once is a deeper inhibition than any approved drug delivers. Reassuringly, in the 67-patient HS trial, treatment-emergent infections occurred in 13.3% on eltrekibart vs 18.2% on placebo, all mild-to-moderate, with no neutropenia signal flagged [3]. That number is too small to be definitive - the 352-patient confirmatory trial is where serious bacterial infection rates become readable. CXCL8 also has documented cardiovascular biology per Open Targets (CXCL8 gene page lists evidence for coronary artery disease, ischemic stroke, and myocardial infarction associations) [7]. Long-term ligand neutralization may produce cardiovascular consequences that 16-week trials won't catch. Execution risk: the UC combination uses mirikizumab as the backbone, and the commercial play only works if Omvoh has meaningful market penetration. Lilly's IBD launch has been steady but not explosive. Commercial risk is real even on positive data. Payer dynamics in UC are brutal - insurers gate biologic combinations behind step therapy. Combination biologic regimens in IBD have historically priced in the $60K-100K range per patient per year (assumption, not sourced), and prior authorization friction will be substantial unless the efficacy delta over current standard of care is large and obvious.

Worth watching, with the conviction case downgraded. The published HS data missed its frequentist primary - the headline win lives or dies on the 352-patient confirmatory trial. Three things keep this on the radar. First, Lilly is running confirmatory HS and combination UC trials in parallel. Companies don't do that for marginal programs. They do it when they believe the mechanism generalizes across neutrophil-driven inflammation. If both read positive, the indication list expands fast: COPD exacerbations, severe asthma, alcohol-associated hepatitis, additional IBD subtypes. Asset value scales nonlinearly with mechanism validation across diseases. Second, the combination strategy with mirikizumab is interesting. Lilly's $65B annual revenue [4] means it can afford to bundle assets to defend a category. The UC biologic opportunity is meaningful - the broader UC drug market is ~$8-11B globally in 2026 with biologics taking ~70% share, projected to ~$15B by 2030-2035 [8]. The HS market is smaller but the fastest-growing dermatology segment, ~$1B-$1.5B globally in 2026, projected to ~$4.4B across top-7 markets by 2035 (10% CAGR) post-adalimumab/secukinumab/bimekizumab [9]. Third, NCT04493502 [3] remains the first published human efficacy readout for any anti-ELR+ CXC chemokine antibody - even with a missed primary, the directional signal and the favorable infection balance are real data points. When to check back: NCT06046729 HS readout (estimated H2 2026 to H1 2027), the UC Phase 2 readout (estimated H1 to H2 2027), or any Lilly earnings-call mention of eltrekibart Phase 3 commitment [5]. If Lilly stays quiet on this asset through 2026, that's a tell.